{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:40:22Z","timestamp":1790671222236,"version":"4.1.0"},"reference-count":20,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,1]]},"abstract":"\n Aim:<\/jats:bold>\n Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL)\u00a0and follicular lymphoma (FL).\n Methods:<\/jats:bold>\n The primary outcome was direct and indirect costs in patients with ALL\/DLBCL\/FL who received HSCT between 2010 and 2014. Costs were evaluated two to four quarters before to eight quarters after HSCT.\n Results:<\/jats:bold>\n Among 258 patients with HSCT, direct costs were \u20ac290,125\/patient (pediatric ALL), \u20ac246,266\/patient (adult ALL), \u20ac230,399\/patient (DLBCL\/FL allogeneic) and \u20ac107,457\/patient (DLBCL\/FL autologous). Indirect costs with HSCT were \u20ac52,939\/patient (adult ALL), \u20ac20,285\/patient (DLBCL\/FL allogeneic) and \u20ac29,881\/patient (DLBCL\/FL autologous).\n Conclusion:<\/jats:bold>\n Direct and indirect costs associated with HSCT are substantial for patients with ALL, DLBCL and FL. Novel therapies that reduce HSCT use could reduce medical costs.\n <\/jats:p>","DOI":"10.2217\/cer-2018-0100","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T17:24:07Z","timestamp":1544030647000},"page":"121-131","source":"Crossref","is-referenced-by-count":18,"title":["Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany"],"prefix":"10.57264","volume":"8","author":[{"given":"Lukas","family":"Mayerhoff","sequence":"first","affiliation":[{"name":"Elsevier Health Analytics, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[{"name":"Elsevier Health Analytics, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Hickstein","sequence":"additional","affiliation":[{"name":"Health Risk Institute, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyab","family":"Salimullah","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Prieur","sequence":"additional","affiliation":[{"name":"Elsevier Health Analytics, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simu K","family":"Thomas","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","unstructured":"International Agency for Research on Cancer\n . \n GLOBOCAN 2012: estimated cancer incidence mortality and prevalence worldwide in 2012\n . \n Estimated age-standardised incidence and mortality rates: men\n (\n 2012\n ). \n http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx\n ."},{"issue":"17","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan EA","year":"2006","unstructured":"Copelan EA . Hematopoietic stem-cell transplantation . N. Engl. J. Med. 354 ( 17 ), 1813 \u2013 1826 ( 2006 ).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding AK","year":"2007","unstructured":"Fielding AK , Richards SM , Chopra R Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study . Blood. 109 ( 3 ), 944 \u2013 950 ( 2007 ).","journal-title":"Blood."},{"issue":"6","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger T","year":"2017","unstructured":"Terwilliger T , Abdul-Hay M . Acute lymphoblastic leukemia: a comprehensive review and 2017 update . Blood Cancer J. 7 ( 6 ), e577 ( 2017 ).","journal-title":"Blood Cancer J."},{"issue":"4","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.hemonc.2017.05.004","article-title":"Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances","volume":"10","author":"Epperla N","year":"2017","unstructured":"Epperla N , Hamadani M . Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances . Hematol. Oncol. Stem Cell Ther. 10 ( 4 ), 277 \u2013 284 ( 2017 ).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"6","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474086.2017.1326812","article-title":"Follicular lymphomas and their transformation: past and current research","volume":"10","author":"Mendez M","year":"2017","unstructured":"Mendez M , Torrente M , Provencio M . Follicular lymphomas and their transformation: past and current research . Expert Rev. Hematol. 10 ( 6 ), 515 \u2013 524 ( 2017 ).","journal-title":"Expert Rev. Hematol."},{"issue":"8","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.zefq.2014.08.022","article-title":"[STandardized Reporting Of Secondary data Analyses (STROSA)-a recommendation]","volume":"108","author":"Swart E","year":"2014","unstructured":"Swart E , Schmitt J . [STandardized Reporting Of Secondary data Analyses (STROSA)-a recommendation] . Z Evid. Fortbild. Qual. Gesundhwes. 108 ( 8\u20139 ), 511 \u2013 516 ( 2014 ).","journal-title":"Z Evid. Fortbild. Qual. Gesundhwes."},{"issue":"2","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pds.1471","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"17","author":"International Society of Pharmacoepidemiology","year":"2008","unstructured":"International Society of Pharmacoepidemiology . Guidelines for good pharmacoepidemiology practices (GPP) . Pharmacoepidemiol. Drug Saf. 17 ( 2 ), 200 \u2013 208 ( 2008 ).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/pds.3895","article-title":"Characteristics and external validity of the German Health Risk Institute (HRI) Database","volume":"25","author":"Andersohn F","year":"2016","unstructured":"Andersohn F , Walker J . Characteristics and external validity of the German Health Risk Institute (HRI) Database . Pharmacoepidemiol. Drug Saf. 25 ( 1 ), 106 \u2013 109 ( 2016 ).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"e_1_3_6_12_2","unstructured":"Institute for Quality and Efficiency in Health Care\n . \n Ponatinib \u2013 assessment according to \u00a7 35a (para. 1 sentence 10) Social Code Book V (dossier assessment [G13-02]\n (\n 2013\n ). \n www.iqwig.de\/en\/projects-results\/projects\/health-economic\/g13-02-ponatinib-assessment-according-to-35a-para-1-sentence-10-social-code-book-v-dossier-assessment.3691.html\n ."},{"key":"e_1_3_6_13_2","unstructured":"Institute for Quality and Efficiency in Health Care\n . \n Brivaracetam \u2013 benefit assessment according to \u00a735a Social Code Book V [dossier assessment A16-08]\n (\n 2016\n ). \n www.iqwig.de\/en\/projects-results\/projects\/drug-assessment\/a16-08-brivaracetam-benefit-assessment-according-to-35a-social-code-book-v.7228.html\n ."},{"key":"e_1_3_6_14_2","unstructured":"Institute for Quality and Efficiency in Health Care\n . \n Sacubitril\/valsartan \u2013 benefit assessment according to \u00a735a Social Code Book V [dossier assessment A15-60]\n (\n 2016\n ). \n www.iqwig.de\/download\/A15-60_Sacubitril-valsartan_Extract-of-dossier-assessment.pdf\n ."},{"key":"e_1_3_6_15_2","unstructured":"Institute for Quality and Efficiency in Health Care\n . \n Secukinumab (plaque psoriasis) \u2013 benefit assessment according to \u00a735a Social Code Book V [dossier assessment Nr. 515]\n (\n 2016\n ). \n www.iqwig.de\/download\/A17-08_Secukinumab_Nutzenbewertung-35a-SGB-V_V1-0.pdf\n ."},{"key":"e_1_3_6_16_2","unstructured":"Institute for Quality and Efficiency in Health Care\n . \n Tasimelteon \u2013 benefit assessment according to \u00a735a Social Code Book V [dossier assessment Nr. 454]\n (\n 2016\n ). \n www.iqwig.de\/download\/G16-08_Tasimelteon_Bewertung-35a-Abs1-Satz10-SGB-V.pdf\n ."},{"issue":"11","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/13696998.2016.1192549","article-title":"Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review","volume":"19","author":"Dombret H","year":"2016","unstructured":"Dombret H , Thomas X , Chevallier P Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review . J. Med. Econ. 19 ( 11 ), 1034 \u2013 1039 ( 2016 ).","journal-title":"J. Med. Econ."},{"issue":"6","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/17843286.2017.1314091","article-title":"Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium","volume":"72","author":"Maertens J","year":"2017","unstructured":"Maertens J , Graux C , Breems D Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium . Acta Clin. Belg. 72 ( 6 ), 429 \u2013 433 ( 2017 ).","journal-title":"Acta Clin. Belg."},{"issue":"5","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428194.2017.1375100","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"59","author":"Maziarz RT","year":"2018","unstructured":"Maziarz RT , Hao Y , Guerin A Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma . Leuk. Lymphoma 59 ( 5 ), 1133 \u2013 1142 ( 2018 ).","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/ijh-2016-0001","article-title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant","volume":"5","author":"Maziarz RT","year":"2016","unstructured":"Maziarz RT , Gu\u00e9rin A , Gauthier G Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant . Int. J. Hematol. Oncol. 5 ( 2 ), 63 \u2013 75 ( 2016 ).","journal-title":"Int. J. Hematol. Oncol."},{"key":"e_1_3_6_21_2","volume-title":"American Society of Hematology 59th Annual Meeting & Exposition","author":"Zhang X","year":"2017","unstructured":"Zhang X , Song H , Lopez-Gonzalez L , Jariwala-Parikh K , Cong Z . Economic burden of hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) in the US [abstract #3376] . American Society of Hematology 59th Annual Meeting & Exposition . GA, USA , December 9\u201312 2017 ."},{"issue":"2","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail NS","year":"2013","unstructured":"Majhail NS , Mau LW , Denzen EM , Arneson TJ . Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database . Bone Marrow Transplant. 48 ( 2 ), 294 \u2013 300 ( 2013 ).","journal-title":"Bone Marrow Transplant."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2018-0100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:32:32Z","timestamp":1679229152000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2018-0100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.2217\/cer-2018-0100"],"URL":"https:\/\/doi.org\/10.2217\/cer-2018-0100","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}